| Item Type | Name |
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-6
|
|
Academic Article
|
Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine.
|
|
Academic Article
|
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
|
|
Academic Article
|
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
|
|
Academic Article
|
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
|
|
Academic Article
|
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
|
|
Academic Article
|
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
|
|
Academic Article
|
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
|
|
Academic Article
|
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.
|
|
Academic Article
|
Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
|
|
Academic Article
|
Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.
|
|
Academic Article
|
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.
|
|
Academic Article
|
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
|
|
Academic Article
|
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Diffuse Large B-Cell Lymphoma Version 1.2016.
|
|
Academic Article
|
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
|
|
Academic Article
|
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
|
|
Academic Article
|
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
|
|
Academic Article
|
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
|
|
Academic Article
|
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
|
|
Academic Article
|
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.
|
|
Academic Article
|
NCCN Guidelines? Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
|
|
Academic Article
|
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
|
|
Academic Article
|
Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.
|
|
Academic Article
|
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.
|